Charcot–Marie–Tooth Neuropathy (CMT)

Charcot–Marie–Tooth (CMT) is a group of inherited nerve disorders that slowly damage the long nerves of the arms and legs. These nerves carry signals that let your muscles move and your skin feel touch, pain, and temperature. In CMT, the nerve “wiring” (the axon) and/or the “insulation” (myelin) is faulty because of a change (variant) in a gene you were born with. Over years, this makes the muscles of the feet, legs, and hands weaker and thinner, causes high arches or hammertoes, makes walking less steady, and reduces feeling in the feet and hands. Most people notice problems in childhood, the teen years, or early adult life, and symptoms usually progress slowly. CMT does not affect the brain or shorten life for most people, but it can cause disability if not recognized and managed. NCBI+2NINDS+2

Charcot-Marie-Tooth (CMT) is a group of inherited peripheral nerve disorders. “Peripheral nerves” are the long electrical cables that carry signals between the spinal cord/brain and the muscles and skin. In CMT, genetic changes (mutations) make these nerves demyelinate (the insulation thins) or degenerate (the wire itself wears out). Over years, this leads to muscle weakness and wasting in the feet and lower legs first, high arched feet (pes cavus) or hammertoes, foot drops, ankle sprains, unsteady walking, and later hand weakness and sensory loss (numbness, reduced vibration, pain). CMT usually does not shorten life but can reduce mobility and hand function. Today, care is supportive—physiotherapy, bracing, pain management, and sometimes surgery for foot deformity—while gene-targeted therapies are being researched. NCBI

---

Other names

• Hereditary motor and sensory neuropathy (HMSN) – older umbrella name that means the same thing as CMT.

• Peroneal muscular atrophy – an older term describing the typical lower-leg muscle wasting first seen in many people with CMT.

• Hereditary peripheral neuropathy – broad term that includes CMT and related conditions such as HNPP (hereditary neuropathy with liability to pressure palsies). NCBI+1

---

Types

Doctors group CMT by what part of the nerve is mainly affected and by inheritance pattern. You might see a letter–number label (like CMT1A). Key families of types include:

• CMT1 (demyelinating, usually autosomal dominant): The myelin “insulation” is mostly affected. Nerve conduction is slow on testing (often ≤35 m/s). CMT1A (PMP22 duplication) is the most common worldwide. CMT1B involves MPZ variants. Symptoms often begin in childhood. NCBI+1

• CMT2 (axonal, often autosomal dominant): The axon (nerve fiber) is mostly affected. Nerve conduction speeds are near-normal or only mildly slow, but signal size is reduced. MFN2 is a frequent cause (CMT2A). Onset is often teens–20s. NCBI

• CMTX (X-linked): Usually due to GJB1 variants (connexin-32). Males tend to be more affected; females can have milder signs. Some people have brief episodes of weakness after illness. NCBI

• CMT4 (autosomal recessive): Demyelinating forms often with earlier onset and faster progression; examples include SH3TC2 and GDAP1-related CMT. More common in regions with higher rates of parental relatedness. NCBI

• Intermediate CMT: Nerve studies show speeds between classic demyelinating and axonal ranges, reflecting mixed biology (both myelin and axon issues). NCBI

• Related disorders: HNPP (usually PMP22 deletion) causes recurrent focal nerve palsies after minor compression; it is related but distinct from CMT1A. Genomics Education Programme

CMT is among the most common inherited nerve disorders, with a frequently cited prevalence around 1 in 2,500 people worldwide, though estimates vary by region. pfmjournal.org

There are many different types of CMT. How a person inherits CMT, how old they are when they first have symptoms, and whether their CMT affects axons or myelin are all factors in what symptoms the person has.

There are several different types of CMT:

• CMT1 is caused by problems in the myelin sheath.
  • A subtype of CMT1 called CMT1A is the most common type of CMT. It happens when a gene that is important to making the myelin sheath is duplicated and too much of the protein PMP22 is made in the cells that wrap around the axon. Symptoms of CMT1A often begin during childhood and slowly get worse over time. Another type of CMT, called Hereditary Neuropathy with liability to Pressure Palsy (HNPP), results from the deletion of one copy of the PMP22 gene. It causes recurring nerve damage in episodes, triggered by pressure on affected nerves. Muscle weakness is more common in people with CMT1A, while numbness and tingling are more common in HNPP.
  • CMT1B is caused by changes (mutations) in the gene (MPZ) responsible for making another key part of the myelin sheath. CMT1B produces symptoms similar to those found in CMT1A. Onset of symptoms for CMT1B can be in infants, children, or adults.
• CMT2 affects the axon of peripheral nerve cells and is less common than CMT1. There are more than a dozen types of CMT2, linked to specific gene changes. In addition to the more typical symptoms of CMT, some types of CMT2 can cause speech or breathing problems due to nerve damage.
• CMT4 is a rare and severe form of CMT that has a profound impact on peripheral nerves. While CMT1 and CMT2 are usually dominantly inherited, CMT4 is recessive. In a dominant inheritance, only one parent must pass on the gene for a child to have the condition. In recessive inheritance, both parents must pass on the gene for a child to be affected, even if the parents don’t have the condition themselves. CMT4 usually begins in childhood with leg weakness, and many lose the ability to walk by their teen years.
• CMTX is the second most common form of CMT, caused by mutations in genes on the X chromosome that make proteins in the myelin sheath. Symptoms include muscle weakness, foot deformities, and nerve issues. Boys typically have moderate to severe symptoms starting in late childhood, while girls may have milder symptoms or none.

---

Causes

Below are common and instructive causes of CMT. Each item explains the gene or mechanism, inheritance pattern (if known), and simple “what it does” in the nerve. (There are many more—hundreds of genes have been linked—but these are representative.)

1. PMP22 duplication (CMT1A): Extra copies of the PMP22 gene make too much myelin protein, which disrupts myelin structure. This produces slow nerve conduction and classic CMT1 features. Autosomal dominant. NCBI

2. PMP22 deletion (HNPP): One missing copy lowers PMP22, making myelin fragile to pressure; people get recurrent palsies (e.g., foot drop after crossing legs). Related to CMT spectrum. Autosomal dominant. Genomics Education Programme

3. MPZ variants (CMT1B and others): Myelin Protein Zero is a key myelin “glue.” Pathogenic variants alter compaction of myelin, slowing signals and causing weakness and numbness. Autosomal dominant (often). NCBI

4. GJB1/Connexin-32 (CMTX1): A gap-junction protein in Schwann cells and neurons; faulty cell-to-cell communication causes mixed demyelinating/axonal neuropathy. X-linked. NCBI

5. MFN2 variants (CMT2A): Mitofusin-2 controls mitochondrial fusion and transport along long axons. Defects break axonal energy delivery, causing axonal degeneration. Autosomal dominant. NCBI

6. NEFL variants (CMT2E/1F): Neurofilament light polypeptide supports axonal skeleton; variants destabilize axons, leading to mixed phenotypes and variable conduction speeds. AD. NCBI

7. GDAP1 variants (CMT2K or CMT4A): A mitochondrial fission-related protein; recessive forms can be severe and early-onset; dominant forms milder. Affects axonal integrity. NCBI

8. SH3TC2 variants (CMT4C): Protein involved in endocytic trafficking in Schwann cells; recessive demyelinating CMT with scoliosis common. NCBI

9. HSPB1 variants (CMT2F/dHMN2B): Small heat-shock chaperone; variants impair protein handling in motor axons, causing distal weakness and cramps. Usually AD. NCBI

10. HSPB8 variants (CMT2L): Another small heat-shock protein; faulty protein quality control leads to axonal loss, especially in motor fibers. AD. NCBI

11. TRPV4 variants (CMT2C): A calcium-permeable channel; certain variants cause axonal neuropathy with voice changes or breathing weakness because of laryngeal/diaphragm involvement. AD. NCBI

12. ATP7A variants (Menkes/CMT2A-like): Copper transport defects can present with axonal neuropathy in milder alleles; impacts enzymes needed for axon maintenance. X-linked. NCBI

13. FIG4 variants (CMT4J): Phosphoinositide metabolism protein; recessive variants disrupt endolysosomal trafficking, leading to rapid-onset or stepwise weakness. AR. NCBI

14. MTMR2 variants (CMT4B1): Lipid phosphatase regulating myelin membrane homeostasis; causes myelin outfoldings and severe demyelinating neuropathy. AR. NCBI

15. MTMR13/SBF2 variants (CMT4B2): Partner of MTMR2; similar mechanism with myelin outfoldings, early onset, and sensory loss. AR. NCBI

16. LITAF variants (CMT1C): Affects endosomal protein sorting in Schwann cells; causes slowly progressive demyelinating neuropathy. AD. NCBI

17. EGR2 variants (CMT1D): Transcription factor needed for myelin gene expression; variants impair Schwann-cell myelination. AD. NCBI

18. PRX variants (CMT4F/Dejerine–Sottas): Periaxin stabilizes non-compact myelin; recessive variants cause severe childhood-onset demyelinating neuropathy with areflexia. AR. NCBI

19. DNM2 variants (CMT-intermediate): Dynamin-2 regulates membrane scission; certain variants produce intermediate conduction speeds and mixed pathology. AD. NCBI

20. SORD deficiency (CMT2-like): Biallelic SORD variants cause accumulation of toxic sorbitol that injures axons; important because it suggests a potential metabolic treatment pathway (still under study). AR. NCBI

Takeaway: Although genes and pathways differ, the common end-result is slow, length-dependent damage to the longest nerves, so feet and legs are affected first, then hands. Genetic testing panels can identify a cause in a large share of cases. ARUP Consult

---

Symptoms

1. Foot weakness and foot drop: Toes catch the ground or you slap the foot while walking because ankle-lifting muscles are weak. Stairs and uneven ground are hard. NINDS

2. High arches (pes cavus) or hammertoes: The foot shape changes over time because muscle balance around the foot and ankle is off. Shoes may feel tight or painful. NINDS

3. Frequent tripping or falls: Poor ankle control and reduced sensation make balance harder, especially in the dark or on bumpy surfaces. NINDS

4. Calf thinning (“stork legs”): The lower-leg muscles slowly shrink from disuse and nerve supply loss, giving a thin-leg look. NINDS

5. Hand weakness: Later on, small hand muscles weaken; buttons, zippers, jar lids, and writing can be difficult. NINDS

6. Numbness or reduced feeling: Especially in the feet and toes at first; you may not feel blisters or cuts easily. NINDS

7. Pins-and-needles or burning: Abnormal nerve signals can cause tingling, buzzing, or mild burning discomfort in feet and later hands. NINDS

8. Ankle sprains and instability: Weak peroneal muscles and poor position sense increase the risk of rolling an ankle. NINDS

9. Cramps and fatigue: Overworked muscles cramp easily, and walking long distances feels tiring. NINDS

10. Absent or reduced reflexes: The tapping test at the ankle or knee is often weak or absent because the reflex arc is impaired. NCBI

11. Cold feet or color changes: Poor autonomic nerve function can affect small blood vessels, making feet look pale or feel cold. NINDS

12. Pain from joint stress: Abnormal foot mechanics strain joints and tendons; some people develop chronic foot, ankle, or knee pain. NINDS

13. Scoliosis (curved spine) in some subtypes: Especially in certain recessive forms (e.g., SH3TC2-related). NCBI

14. Tremor in some types: A fine hand tremor (Roussy–Lévy phenotype) can occur with specific myelin gene variants. NCBI

15. Breathing or voice problems (rare): Certain TRPV4- or MFN2-related forms can involve the diaphragm or laryngeal muscles. NCBI

---

Diagnostic tests

A) Physical examination

1. Gait and posture exam: The clinician watches you walk, turn, and stand on heels and toes. They look for foot drop, ankle wobble, toe clawing, and high arches. Subtle changes in the way you plant your foot often give the first clues. NINDS

2. Muscle strength grading (MRC scale): Each major muscle group in the feet, legs, and hands is tested against resistance. In CMT, the ankle dorsiflexors and evertors are usually weakest early on.

3. Reflex testing: A soft hammer taps tendons at the ankle and knee. In CMT, reflexes are often reduced or absent in the ankles first, reflecting a damaged reflex arc. NCBI

4. Sensation mapping: Light touch, pinprick, vibration (with a tuning fork), and position sense are checked from toes upward. A “stocking” pattern of reduced feeling suggests length-dependent neuropathy. NINDS

5. Foot structure and skin check: The examiner looks for pes cavus, hammertoes, calluses, pressure sores, and signs of poor footwear fit, which guide orthotic needs. NINDS

B) Manual bedside tests

6. Heel-walk and toe-walk: Standing on heels tests ankle dorsiflexion; standing on toes tests calf strength. Difficulty with heel-walking often points to early foot-drop weakness.

7. Single-leg balance (Romberg with eyes closed): Worsening sway with eyes closed suggests impaired position sense from sensory nerve damage.

8. Hand dexterity tasks (buttoning, peg test): Quick practical tasks reveal small-hand muscle weakness and coordination issues.

9. Tinel’s sign at entrapment sites: Gentle tapping over the peroneal nerve at the fibular head or ulnar nerve at the elbow may trigger tingling if nerves are vulnerable, guiding splinting to avoid compressions (especially in HNPP-related cases). Genomics Education Programme

10. Foot flexibility and Achilles tightness tests: Manual stretching checks for contractures that worsen gait and may need therapy or bracing.

C) Laboratory & pathological tests

11. Targeted genetic testing (multigene panel or exome): The most definitive test for CMT is finding a disease-causing variant in a known gene. Modern panels first look for PMP22 duplication/deletion (CMT1A/HNPP), then sequence dozens to hundreds of other CMT genes. Yield varies by phenotype and ancestry. NCBI+1

12. PMP22 dosage analysis (duplication/deletion): A specialized lab method (e.g., MLPA, qPCR) counts gene copies to detect CMT1A or HNPP quickly and cost-effectively. Genomics Education Programme

13. Metabolic screens (to exclude mimics): Routine labs (glucose/HbA1c, B12, TSH, SPEP, renal/hepatic panels) help ensure there isn’t a non-genetic cause mixed in, since diabetes, thyroid disease, or B12 deficiency can worsen neuropathy. American Academy of Neurology

14. Nerve biopsy (in select cases): Rarely needed today but may be considered when genetics is unrevealing and inflammatory neuropathy is a concern. In CMT1, biopsy can show myelin “onion bulbs” from repeated demyelination/remyelination. NCBI

15. CSF protein (to exclude CIDP): If weakness progresses unusually fast or there’s suspicion for an immune neuropathy, a spinal tap can show high protein in CIDP—a different, treatable condition—helping avoid misdiagnosis. uems-neuroboard.org+1

D) Electrodiagnostic tests

16. Nerve conduction studies (NCS): Sticky electrodes deliver small electrical pulses to nerves and record responses. Demyelinating CMT (CMT1) shows slow conduction velocities, while axonal CMT (CMT2) shows lower response sizes with near-normal speeds. This helps pick the type and guides genetic testing. NCBI+1

17. Electromyography (EMG): A fine needle listens to muscle electrical activity. In CMT, EMG shows patterns of chronic nerve loss with reinnervation, supporting a length-dependent neuropathy rather than a primary muscle disease. PMC

18. Autonomic reflex testing (when symptoms suggest): Heart-rate variability, sweat testing, or blood-pressure responses can document autonomic involvement in select patients. American Academy of Neurology

19. Repetitive nerve stimulation (to exclude junction disorders): Used if fatigable weakness raises concern for a neuromuscular junction problem (like myasthenia), helping confirm that CMT is the right category. PMC

E) Imaging tests

20. Musculoskeletal imaging (X-ray/MRI/ultrasound) for feet and ankles: Imaging maps high arches, hammertoes, tendon imbalances, or ankle instability. It guides orthotics, splinting, or surgery planning. Peripheral nerve ultrasound may show enlarged nerves in demyelinating forms. NINDS

Non-pharmacological treatments (therapies & others)

1. Individualized physiotherapy program – A PT builds a plan to keep joints flexible, maintain strength/endurance, improve balance, and reduce falls. Purpose: preserve function and independence. Mechanism: task-specific strengthening (especially dorsiflexors and intrinsic foot muscles), stretching tight plantarflexors, and balance training to counter distal weakness and sensory loss. Evidence reviews support targeted exercise to improve activities of daily living in CMT. PMC+1

2. Occupational therapy (OT) – Trains energy-saving methods, hand function strategies, and adaptive tools (button hooks, built-up pens, jar openers) to protect joints and maintain self-care and work tasks. Purpose: maximize independence. Mechanism: activity analysis plus assistive devices for weak intrinsic hand muscles and sensory loss. cmtausa.org+1

3. Ankle-foot orthoses (AFOs) – Custom braces (carbon-fiber or polypropylene; sometimes hinged) that support the ankle and foot to reduce foot drop, improve toe clearance, and stabilize the hindfoot. Purpose: safer, less tiring gait. Mechanism: external lever arms substitute for weak tibialis anterior/peroneals. Trials and patient-reported studies show faster gait and higher satisfaction versus no AFOs. PubMed+2PMC+2

4. Footwear optimization & insoles – Wider toe-box shoes, rocker soles, cushioned insoles, and lateral wedging (if needed) accommodate claw toes/cavus and address ankle instability. Purpose: reduce pain and trips. Mechanism: redistributes plantar pressures and improves rollover. PMC

5. Balance and falls-prevention training – Includes dynamic balance tasks, obstacle negotiation, and home hazard review. Purpose: cut fall risk from distal weakness and proprioceptive loss. Mechanism: repeated exposure builds compensatory visual/vestibular strategies. PMC

6. Contracture management (stretching/night splints) – Gentle daily calf/plantar fascia stretches; occasional night casting/splints in children to maintain dorsiflexion. Purpose: prevent fixed equinus and reduce tripping. Mechanism: low-load prolonged stretch counters muscle imbalance. CMT Australia

7. Hand therapy – Targeted grip/pinch strengthening and thumb web stretching plus custom thumb opponens splints. Purpose: slow hand functional decline. Mechanism: neuromuscular re-education and joint protection techniques. cmtausa.org

8. Aerobic conditioning – Low-impact options (cycling, swimming, elliptical). Purpose: maintain cardiovascular fitness and reduce fatigue. Mechanism: improves aerobic capacity and activity tolerance without overloading weak distal muscles. PMC

9. Pain self-management & CBT-informed strategies – Education on pacing, sleep, mood, and coping skills. Purpose: reduce pain interference and improve quality of life. Mechanism: changes pain processing and behavior around activity. NICE

10. Functional electrical stimulation (FES) for foot drop – Peroneal nerve stimulators in select cases. Purpose: improve toe clearance in swing phase. Mechanism: stimulates dorsiflexors during gait. (Evidence is mixed; trial by specialist recommended.) PMC

11. Assistive devices – Trekking poles/canes on uneven ground; bathroom grab bars; ankle braces for sports. Purpose: reduce falls and fear of falling. Mechanism: increases base of support and external stability. PMC

12. Weight management & nutrition counseling – Extra body weight increases energy cost of walking and joint load in weak ankles. Purpose: preserve mobility. Mechanism: caloric balance and nutrient-dense foods. (No disease-specific diet; see “What to eat” below.) cmtausa.org

13. Skin/foot care education – Daily checks for pressure spots or ulcers in numb feet; nail and callus care by trained providers. Purpose: prevent wounds and infections. Mechanism: early detection with protective footwear. Mayo Clinic

14. Home/workplace ergonomics – Modify work height, mattress, keyboards, and mouse size; reduce trip hazards. Purpose: conserve energy and protect joints. Mechanism: task redesign and adaptive tech. cmtausa.org

15. Fatigue management (pacing/interval planning) – Break tasks into smaller bouts; use seated tasks for fine motor work. Purpose: maintain participation without flare-ups. Mechanism: avoids “boom-and-bust.” NICE

16. Community-based exercise (with CMT-aware programs) – Group classes (gentle Pilates, aquatic therapy) tailored for ankle instability. Purpose: adherence and social support. Mechanism: supervised progressive load with safety adjustments. cmtausa.org

17. Orthopedic surveillance – Regular review by foot/ankle specialists to watch for progressive cavovarus, claw toes, and Achilles tightness—earlier less-invasive interventions may help. Purpose: timely surgery when needed. Mechanism: staged approach based on deformity flexibility. PMC

18. Education on neurotoxic medications to avoid – Some chemo and other drugs (e.g., vincristine) can cause severe neuropathy in people with CMT; teams should screen meds. Purpose: avoid iatrogenic worsening. Mechanism: substitution with safer agents when possible. NCBI

19. Sleep & mood optimization – Treat insomnia, anxiety, and depression to lower pain sensitivity and improve rehab participation. Purpose: better daytime function. Mechanism: improves central pain modulation. NICE

20. Clinical trial participation – Access to investigational approaches (e.g., PMP22-targeting strategies for CMT1A). Purpose: potential benefit and advancement of care. Mechanism: gene/pathway-targeted interventions under study. (No approved disease-modifying therapy yet.) NCBI

---

Drug treatments

Important context: FDA approvals below are for other neuropathic pain conditions (e.g., diabetic peripheral neuropathy, postherpetic neuralgia). In CMT, clinicians may adapt these for painful neuropathy on an individualized, off-label basis. Start low, go slow, and review interactions and organ function.

1. Pregabalin (Lyrica / Lyrica CR) — Class: gabapentinoid anticonvulsant. Typical dosing for neuropathic pain begins 150 mg/day in divided doses; can titrate to 300–600 mg/day as tolerated; Lyrica CR is once-daily; adjust for renal function. Purpose: reduce burning/tingling neuropathic pain and improve sleep. Mechanism: α2δ-subunit calcium-channel modulation, reducing excitatory neurotransmitter release. Common adverse effects: dizziness, somnolence, edema, weight gain, blurred vision. (FDA-approved for DPN/PHN; off-label in CMT.) FDA Access Data+2FDA Access Data+2

2. Gabapentin (Neurontin/Gralise) — Class: gabapentinoid. Typical titration 300 mg at night → 300 mg TID (commonly 900–1800 mg/day, sometimes up to 3600 mg/day); adjust for kidney function. Purpose: neuropathic pain relief and better sleep continuity. Mechanism: α2δ-subunit modulation similar to pregabalin. Adverse effects: dizziness, somnolence, ataxia; caution with CNS depressants and in respiratory disease. (PHN indication; off-label in CMT.) FDA Access Data+2FDA Access Data+2

3. Duloxetine (Cymbalta) — Class: SNRI antidepressant. Dosing: start 30 mg/day for 1 week then 60 mg/day; some need 120 mg/day. Purpose: neuropathic pain relief and mood support. Mechanism: enhances descending noradrenergic/serotonergic inhibition of pain. Side effects: nausea, dry mouth, hyperhidrosis; boxed warning for suicidality; avoid with MAOIs; watch for serotonin syndrome. (FDA-approved for DPN; off-label in CMT.) FDA Access Data+2FDA Access Data+2

4. Topical Capsaicin 8% patch (Qutenza) — Class: topical TRPV1 agonist. Applied in clinic for PHN/DPN; can reduce peripheral sensitization after a brief burning phase. Purpose: focal neuropathic pain (e.g., feet). Mechanism: defunctionalizes nociceptor endings. Adverse effects: local erythema/burning; avoid on broken skin; protective handling needed. (Clinic-applied; off-label in CMT.) FDA Access Data+2FDA Access Data+2

5. Topical Lidocaine 5% patch (Lidoderm) / Lidocaine 1.8% (ZTlido) — Class: topical sodium-channel blocker. Up to 12 h on/12 h off (per label for PHN). Purpose: focal pain with allodynia. Mechanism: blocks ectopic discharges in cutaneous afferents. Generally well tolerated; watch for local reactions and excessive dosing. (PHN indication; off-label in CMT.) FDA Access Data+2FDA Access Data+2

6. Amitriptyline (generic) — Class: tricyclic antidepressant. Dosing often 10–25 mg at night, titrating to 25–75 mg if tolerated. Purpose: neuropathic pain and sleep benefit. Mechanism: serotonin-noradrenaline reuptake inhibition plus sodium-channel blockade. Adverse effects: anticholinergic effects, QT prolongation; caution in older adults. (FDA-approved for depression; used off-label for neuropathic pain; label confirms indication scope and safety warnings.) FDA Access Data+1

7. Tramadol — Class: weak μ-opioid agonist + SNRI activity. Dosing often 25–50 mg q6–8h PRN; max per label varies by product; avoid with serotonergic drugs and in seizure risk. Purpose: second-line rescue when first-line neuropathic agents fail. Mechanism: μ-opioid plus monoamine reuptake inhibition. Adverse effects: nausea, dizziness, dependence, serotonin syndrome risk. (FDA-labeled for pain; use cautiously in neuropathic pain.) Lippincott Journals

8. NSAIDs (e.g., ibuprofen/naproxen) — Class: COX inhibitors. Purpose: helpful for musculoskeletal aches from overuse, not for nerve pain itself. Mechanism: reduces inflammatory prostaglandins. Risks: GI, renal, CV effects; lowest effective dose/shortest time. (General FDA labeling across products.) NICE

9. Baclofen — Class: antispasticity agent (GABA-B agonist). Dosing often 5 mg TID titrating upward. Purpose: cramps/spasms some CMT patients report. Mechanism: reduces spinal reflex excitability. Side effects: sedation, weakness; taper slowly to avoid withdrawal. (FDA-approved for spasticity; symptom-driven off-label in CMT.) ClinicalTrials

10. Tizanidine — Class: α2-adrenergic agonist antispastic. Dosing often 2–4 mg at night → titrate. Purpose: nocturnal spasms. Mechanism: presynaptic inhibition in spinal cord. Side effects: hypotension, sedation, LFT elevations; check interactions (CYP1A2). (FDA-approved for spasticity.) PMC

11. Combination therapy examples — Carefully combining first-line agents (e.g., duloxetine + pregabalin) may help some with painful neuropathy when monotherapy is partial; evidence in DPN suggests combination is not always better than optimized monotherapy, so weigh benefits vs added adverse effects. Purpose: augment effect when single drug insufficient. Mechanism: complementary central/peripheral actions. American Academy of Neurology

12. Sleep aids (short-term) and mood treatment — Treat comorbid insomnia/anxiety/depression (e.g., using agents with favorable neuropathic profiles) to improve pain coping. Purpose: reduce pain interference. Mechanism: enhanced descending modulation and better sleep architecture. (Drug choice is individualized.) NICE

(I’m limiting the drug list to the most clinically relevant options with reliable FDA labels; many other brand/generic variants exist, but evidence priorities remain the same. Critically, none is approved specifically for CMT disease modification.)

---

Dietary molecular supplements

(Straight talk: no supplement has proven disease-modifying benefit in CMT. Correct deficiencies and support general health; avoid megadoses. Vitamin C, once promising in mice, failed in multiple human trials.)

1. Vitamin C (ascorbic acid) — Large randomized trials in CMT1A showed no clinical benefit despite animal data. If taken, stay within recommended daily allowance unless advised for another reason. PMC+1

2. Vitamin D — Correct deficiency to support bone and muscle health, especially if balance issues limit outdoor activity. Mechanism: calcium/phosphate metabolism; muscular function. Dose: individualized by 25-OH vitamin D level. Evidence is general, not CMT-specific. cmtausa.org

3. Vitamin B12 — Replace if low to avoid additional neuropathy from deficiency. Mechanism: myelin and DNA synthesis. Dose: per level (oral or IM). NCBI

4. Folate & B6 (avoid high-dose B6) — Correct true deficiency only; excess B6 can cause neuropathy. Mechanism: cofactor roles in nerve metabolism. Dose: diet-based, minimal supplement unless deficient. NCBI

5. Omega-3 fatty acids — General anti-inflammatory effects may support cardiometabolic health and joint comfort, but no CMT-specific proof. Typical food-first approach (fatty fish 2×/week). cmtausa.org

6. Magnesium — If cramps occur and diet is low, repletion may help nocturnal cramps in some people (mixed evidence). Dose: dietary first; supplement cautiously to avoid diarrhea. NICE

7. Coenzyme Q10 — Popular for mitochondrial support; no reliable CMT evidence. Consider only for documented mitochondrial issues per specialist advice. NICE

8. Alpha-lipoic acid — Has DPN data; no CMT-specific disease-modifying evidence. Can cause GI upset and interact with glucose control. Diabetes Research and Clinical Practice

9. Protein adequacy — Adequate protein supports muscle maintenance with PT; food-first approach preferred. cmtausa.org

10. General multivitamin (low-dose) — Safety net for limited diets; avoid megadoses. Mechanism: prevents deficits that could add to neuropathy. cmtausa.org

---

Immunity-booster / regenerative / stem-cell drugs

I cannot list any FDA-approved “immunity booster,” “regenerative,” or “stem-cell” drugs for CMT—because none exist. No stem-cell, gene, or immune drug is approved to treat any CMT subtype in 2025. Research into gene-targeted strategies (for example, reducing PMP22 overexpression in CMT1A) is ongoing, but these are at the clinical-trial or preclinical stage and not approved for dosing outside trials. Using unregulated “stem cells” is risky and not recommended. NCBI

---

Surgeries

Surgery is not for nerves; it rebalances the foot to make walking safer and less painful when deformities become fixed. A foot/ankle surgeon familiar with neuromuscular disorders selects procedures based on whether deformity is flexible or rigid, and on muscle imbalance patterns.

1. Soft-tissue releases (plantar fascia release, tendon lengthening) – Loosen tight plantar fascia or Achilles to correct equinus and allow the heel to contact the ground. Why: reduce forefoot overload and tripping. Often first step in flexible deformity. PMC

2. Tendon transfers (e.g., posterior tibialis or peroneus longus transfer) – Re-route stronger tendons to assist weak dorsiflexors/evertors and balance the foot. Why: improve ankle stability and reduce foot drop. www.elsevier.com

3. Osteotomies (calcaneal valgus-producing osteotomy, first-metatarsal dorsiflexion osteotomy) – Cut and realign bones to correct cavovarus and bring the foot plantigrade. Why: place the foot under the leg for efficient push-off. PMC

4. Triple arthrodesis (fusion of subtalar, talonavicular, calcaneocuboid joints) – For severe, rigid cavovarus with arthritis or when soft-tissue/bony realignment won’t hold. Why: durable correction to relieve pain and allow bracing/walking. PMC

5. Claw-toe corrections (PIP arthrodesis, tendon balancing) – Straighten toes that ulcerate in shoes. Why: reduce pain, improve shoe wear, and prevent skin breakdown. PMC

Outcomes: Contemporary cohorts show meaningful pain and function gains after staged, tailored reconstruction; gait and patient-reported measures improve, though severe baseline deformity may limit full normalization. PubMed+2SAGE Journals+2

---

Preventions

You can’t prevent the genetic cause of CMT, but you can prevent secondary problems:

1. Prevent falls: AFOs, balance training, home safety review. PubMed

2. Prevent ankle sprains: lateral stability exercises, appropriate shoes/bracing. cmtausa.org

3. Prevent contractures: daily calf/hamstring/plantar fascia stretching. CMT Australia

4. Prevent foot ulcers: daily skin checks, seamless socks, pro podiatry care. Mayo Clinic

5. Prevent overuse injuries: pacing, interval rests, activity rotation. NICE

6. Prevent weight-related mobility decline: nutrition guidance and aerobic exercise. cmtausa.org

7. Prevent medication-induced worsening: avoid neurotoxic agents (e.g., vincristine) when alternatives exist; alert all providers you have CMT. NCBI

8. Prevent deconditioning: keep a regular, gentle exercise routine even during flares. PMC

9. Prevent post-op setbacks: do surgery with teams experienced in neurologic cavovarus feet; follow staged rehab. PMC

10. Prevent burnout: use OT energy-conservation and CBT-based coping skills. cmtausa.org+1

---

When to see doctors

• Immediately for a new rapid decline in strength, new severe numbness, or sudden foot drop—CMT is slowly progressive; sudden changes may signal a superimposed problem (entrapment, radiculopathy) that needs urgent evaluation. NCBI

• Soon if pain is uncontrolled, falls are increasing, or braces no longer help—medication adjustment, new AFOs, or surgical review may be needed. cmtausa.org

• Routine: at least annual review with a neuromuscular clinic (PT/OT, orthotist, podiatry/foot-ankle surgeon) to adjust braces, update exercises, and screen for complications. Johns Hopkins Medicine

---

Foods: what to eat & what to avoid

What to eat

1. Lean proteins (fish, poultry, legumes) to support muscle maintenance with PT. cmtausa.org

2. Omega-3-rich fish (e.g., salmon, sardines) twice weekly for general anti-inflammatory benefits. cmtausa.org

3. Colorful vegetables and fruits for micronutrients and fiber. cmtausa.org

4. Whole grains for steady energy during rehab. cmtausa.org

5. Low-fat dairy or fortified alternatives for calcium/vitamin D (or discuss supplements if low). cmtausa.org

What to limit/avoid

1. Excess alcohol (neurotoxic; worsens balance). NCBI
2. Megadose supplements without a deficiency (e.g., high-dose B6 can harm nerves). NCBI
3. Ultra-processed, high-sugar foods that promote weight gain and fatigue. cmtausa.org
4. Crash diets that sap energy for PT/OT. cmtausa.org
5. Unregulated “stem-cell” or “miracle” products marketed for neuropathy. (No approval; risk of harm.) NCBI

---

FAQs

1) Is there a cure for CMT?
No. Care is supportive. Trials of vitamin C in CMT1A failed; research continues. PMC

2) Are there FDA-approved drugs for CMT itself?
No. Medications can help symptoms like neuropathic pain, sleep disturbance, and cramps. NCBI

3) Which pain medicines are first choices for nerve pain?
Guidelines for neuropathic pain often start with amitriptyline, duloxetine, pregabalin, or gabapentin; in CMT these are off-label and individualized. Lippincott Journals

4) Do braces really help?
Yes. AFOs can reduce tripping and fatigue and increase walking speed; fit and material matter. PubMed

5) When is surgery considered?
When foot deformity becomes rigid/painful or bracing fails. Aim: a plantigrade, stable, shoe-friendly foot. Outcomes show meaningful gains in pain and function. PubMed

6) Should I avoid certain medications?
Yes—some drugs (e.g., vincristine) can cause severe neuropathy in people with CMT; always tell clinicians you have CMT. NCBI

7) Is high-dose vitamin C worth trying?
Evidence says no benefit for CMT1A in multiple RCTs. PMC

8) Can exercise make me worse?
Appropriate, supervised exercise is helpful, not harmful. Programs should be tailored to your weakness pattern and balance level. PMC

9) Are stem-cell or gene therapies available?
Not for routine care. Participate only in approved clinical trials if you’re interested. NCBI

10) Will I need a wheelchair?
Many people remain ambulant with bracing, therapy, and (if needed) surgery; mobility devices may still help for distance or uneven terrain. cmtausa.org

11) How do topical treatments fit in?
Lidocaine and capsaicin 8% patches can help focal foot pain/allodynia; they’re approved for PHN/DPN and used off-label in CMT. FDA Access Data+1

12) Is combination drug therapy better?
Sometimes, but not always. An RCT in DPN found duloxetine+pregabalin didn’t clearly beat optimized monotherapy at higher doses. American Academy of Neurology

13) What about fatigue?
Pacing, sleep hygiene, low-impact aerobics, and mood care reduce fatigue and improve function. NICE

14) Who should coordinate my care?
A multidisciplinary neuromuscular clinic (neurologist, PT/OT, orthotist, podiatry/surgeon). Johns Hopkins Medicine

15) Where can I find practical therapy guides?
The Charcot-Marie-Tooth Association offers free PT/OT and bracing guides for clinicians and patients. cmtausa.org+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 01, 2025.